Our Therapies

TZIELD™ Infusion Therapy

TZIELD™ (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. This medication modifies T cell function to preserve beta cell function and is administered as a daily intravenous infusion for 14 consecutive days.

Meet our Infusion Specialists

  • Natali Craig

    Natali Craig

    Product Designer

  • Phoenix Baker

    Phoenix Baker

    Engineering Manager

  • Candice Wu

    Candice Wu

    Backend Developer

  • Lana Steiner

    Lana Steiner

    Product Manager

For Provider

Simplify patient referrals and offer advanced treatment options with our infusion partnership program.

For Patient

There may be a better way to manage your condition – explore infusion therapy.

logo

Cutting-edge infusion therapies and injections for patients with complex chronic conditions and rare diseases.

instagramfacebooklinkedinTwitter

© 2024 violet health®: Infusion Care. All rights reserved.